Two infant formula manufacturers withdrew batches from the market on Monday after France imposed stricter limits on ...
The final, formatted version of the article will be published soon. Background: Sintilimab is an effective PD-1 immune checkpoint inhibitor (ICI) for advanced non-small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results